Paper16040
Metabolic studies in patients with nadolol: oral and intravenous administration.
Dreyfuss J and 4 others. J Clin Pharmacol, 1977. Cited by 77 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Metabolic studies in patients with nadolol: oral and intravenous administration. Papers, record 16040. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16040
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenergic beta-Antagonists | Major topic |
| Propanolamines | Major topic |
| Administration, Oral | |
| Adult | |
| Biotransformation | |
| Chromatography, Gel | |
| Feces | |
| Half-Life | |
| Humans | |
| Hypertension | |
| Injections, Intravenous | |
| Intestinal Absorption | |
| Kinetics | |
| Male | |
| Middle Aged | |
| Models, Biological |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,399,480 | A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38399480 | PubMed |
| 37,538,177 | Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37538177 | PubMed |
| 34,112,223 | Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. | Crit Care | 2021 | https://conductscience.org/library/papers/34112223 | PubMed |
| 29,480,324 | Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers. | Eur J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29480324 | PubMed |
| 27,995,288 | Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children. | Pediatr Cardiol | 2017 | https://conductscience.org/library/papers/27995288 | PubMed |
| 16,331,517 | Ontogeny of drug elimination by the human kidney. | Pediatr Nephrol | 2006 | https://conductscience.org/library/papers/16331517 | PubMed |
| 8,668,660 | In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. | Pharm Res | 1996 | https://conductscience.org/library/papers/8668660 | PubMed |
| 7,272,165 | Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA). | Br J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7272165 | PubMed |
| 7,138,752 | Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7138752 | PubMed |
| 6,150,103 | Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. | J Pharmacokinet Biopharm | 1984 | https://conductscience.org/library/papers/6150103 | PubMed |
| 6,105,067 | Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. | Drugs | 1980 | https://conductscience.org/library/papers/6105067 | PubMed |
| 6,104,498 | Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers. | Br J Clin Pharmacol | 1980 | https://conductscience.org/library/papers/6104498 | PubMed |
| 4,092,726 | Pharmacokinetics of carteolol in relation to renal function. | Eur J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/4092726 | PubMed |
| 3,366,166 | Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects. | Eur J Clin Pharmacol | 1988 | https://conductscience.org/library/papers/3366166 | PubMed |
| 2,858,216 | A comparison of the effects of intravenous propranolol and nadolol on the renal response to hypertonic saline infusion. | Br J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/2858216 | PubMed |
| 2,235,896 | Comparison of single-dose and steady-state nadolol plasma concentrations. | Pharm Res | 1990 | https://conductscience.org/library/papers/2235896 | PubMed |
| 1,676,675 | A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. | Eur J Clin Pharmacol | 1991 | https://conductscience.org/library/papers/1676675 | PubMed |
| 1,653,143 | The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. | Eur J Clin Pharmacol | 1991 | https://conductscience.org/library/papers/1653143 | PubMed |
| 1,349,493 | Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. | Br J Clin Pharmacol | 1992 | https://conductscience.org/library/papers/1349493 | PubMed |
| 1,333,781 | Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. | Br J Clin Pharmacol | 1992 | https://conductscience.org/library/papers/1333781 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16040
GET https://conductscience.org/api/papers/v1/16040/cited_by?page=2